Searching...
12 results for “pharmaceutical timelines”
...on timelines for phase one, two, three, maybe you can just, for the audience that may not work in this industry, very briefly explain phase one, two, three Mhmm. And then where we think there's the biggest kind of, call it excess regulatory burden th
12:39 / 13:53
from transcript12:39 – 13:53
...wait for a pharmaceutical company to say, hey. We need more of the statin or whatnot, or are there people back in the building somewhere, the statin team, the pain killer team, the We, so we we we do both. Right? We certainly, wanna make sure that we
12:54 / 14:08
from transcript12:54 – 14:08
It really just depends on the manufacturing timeline. Got it. That's the problem. Right? That's the determinant. If we we're gonna resubmit manufacturing this year, hopefully, we get it. If we don't pull it off, which is entirely possible, then it ad
9:00 / 10:09
from transcript9:00 – 10:09
...down on timelines for phase one, two, three, maybe you can just, for the audience that may not work in this industry,
11:54 / 13:22
from transcript11:54 – 13:22
...of pharmaceuticals are what matters for the profits. So if you look at the pipeline of a 100 drugs that enter clinical development,
3:10:28 / 3:11:35
from transcript3:10:28 – 3:11:35
...Right? This was not considered like, a pharmaceutical is developed
1:26 / 2:30
from transcript1:26 – 2:30
a product, and they're the regulatory agencies. You know, and everyone is trying to ensure again that, what's, you know, first and foremost is the ability to, discover and commercialize drugs that are safe and effective for humans. That middle part o
27:45 / 28:55
from transcript27:45 – 28:55
drugs were incredibly crude pharmacology. Right? So this was heroin. This was cocaine. This was morphine. Higher retention than than dye stuffs. Right? You know, like, that that's a pretty interesting business. But, obviously, it got a lot more, soph
12:41 / 13:46
from transcript12:41 – 13:46
What are the biggest bottlenecks in translating these innovations into, like, market ready therapies? And how do we address these challenges more effectively if the goal is to get more therapies to to market now that we have more potential therapies?
27:46 / 28:51
from transcript27:46 – 28:51
next step. Yeah. To your point on Tesla Tesla, I mean, the the speed at which you can get cars to market, though, is more regular. Right? Whereas, like, because of these clinical studies, you actually could be ten years for a human, twenty years for
30:33 / 31:48
from transcript30:33 – 31:48
pharma company. That's sort of the long term goal. The way that we think through our company is that in order to actually bring the drug to market, you need a lot of information, you need a lot of experience, and you need the right team. And the way
42:24 / 43:55
from transcript42:24 – 43:55
I really underestimated it. So that's on the dog side. Then we'll have a couple of products. Hopefully, every we wanna have five approvals by 2030 is the vision. So five dog approvals by 2030. Human, I mean, we haven't even begun to design this clini
31:30 / 32:36
from transcript31:30 – 32:36
Have a podcast?
Run your podcast through Clypt
Get ranked clips, hooks, and ready-to-post copy from your own episodes. Free to try.